SRR10900589
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.500
- E2F_TARGETS+0.300
- G2M_CHECKPOINT+0.300
- MYC_TARGETS_V1+0.300
- WNT_BETA_CATENIN_SIGNALING+0.300
- INTERFERON_ALPHA_RESPONSE+0.200
- INTERFERON_GAMMA_RESPONSE+0.200
- KRAS_SIGNALING_DN+0.200
- APICAL_JUNCTION+0.100
- ESTROGEN_RESPONSE_LATE+0.100
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.400
- ADIPOGENESIS-0.300
- ANDROGEN_RESPONSE-0.300
- ANGIOGENESIS-0.300
- HYPOXIA-0.300
- OXIDATIVE_PHOSPHORYLATION-0.300
- PI3K_AKT_MTOR_SIGNALING-0.300
- PROTEIN_SECRETION-0.300
- CHOLESTEROL_HOMEOSTASIS-0.200
- COMPLEMENT-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 10489620-bd98-43ab-9d5f-8ae0c0b1ff7a | — | — | 0.760 |
| 2 | SRR8613722 | — | E | 0.720 |
| 3 | ULC0564T_S96 | — | cohortA1 | 0.719 |
| 4 | SRR8613784 | — | E | 0.717 |
| 5 | TCGA-CN-5367-01A-01R-1436-07 | — | — | 0.703 |
| 6 | SRR8613767 | — | E | 0.695 |
| 7 | SRR4195683 | — | — | 0.695 |
| 8 | C3N-04162 | — | cohortSQ2 | 0.694 |
| 9 | TCGA-56-8307-01A-11R-2296-07 | — | cohortSQ1 | 0.688 |
| 10 | eb5ad680-6080-41fe-982e-e46f90c3849f | — | — | 0.687 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.500 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.300 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.300 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.300 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.300 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.200 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.200 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.200 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.100 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.100 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.100 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.100 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.100 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.100 | Idelalisib | — uncovered |